Phase 3Recruiting
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy
- Sponsor
- GlaxoSmithKline (Industry)
- Enrolment
- 600 planned
- Conditions
- Neoplasms, Endometrial
- Interventions
- Mocertatug rezetecan; Paclitaxel; Doxorubicin
- Ages
- adults, older adults
- Registry
- NCT07286331
From the registry
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating Endometrial Cancer (EC) compared to standard of care. The study also assesses whether Mo-Rez is safe and tolerated well by participants in comparison to standard of care and will help provide a better understanding of the main side effects of the drugs.
Primary outcomes
- Objective response rate (ORR) by BICR
- Progression Free Survival (PFS) by BICR